Abstract
e11568 Background: Trastuzumab has been approved in Japan for adjuvant use in operable breast cancer since 2008. We review our experience with (neo-) adjuvant trastuzumab use in HER2 over-expressin...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
